Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

The Impact of F11R/JAM‑A Peptide Antagonist on Metastasis: Innovative Approach to Combat Breast Cancer | LifeTein Peptide Blog

LifeTein’s Innovative Peptide Antagonist: A New Ally in the Fight Against Breast Cancer Metastasis Breast cancer stands as the most commonly diagnosed cancer in women worldwide and is a leading cause of cancer-related deaths. Among its subtypes, triple-negativ

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

LifeTein’s Innovative Peptide Antagonist: A New Ally in the Fight Against Breast Cancer Metastasis

Breast cancer stands as the most commonly diagnosed cancer in women worldwide and is a leading cause of cancer-related deaths. Among its subtypes, triple-negative breast cancer (TNBC) is particularly notorious for being aggressive and prone to metastasizing to vital organs like the brain, lungs, bones, and liver. Despite being more responsive to chemotherapy, TNBC’s propensity for metastasis poses a significant challenge in cancer treatment.

Recent studies, including notable research from the Medical University of Lodz in Poland, have identified a key factor in TNBC metastasis: increased F11R/JAM-A activity. This protein plays a crucial role in the early stages of cancer cell migration across blood vessels, a precursor to metastasis. Enter LifeTein, a pioneering force in peptide technology, which has made a groundbreaking contribution to this research area.

LifeTein provided a specialized peptide antagonist, named P4D, designed to specifically target and inhibit F11R/JAM‑A. The effectiveness of P4D was rigorously tested in lab models. Remarkably, this antagonist not only curbed the proliferation of TNBC cells but also significantly reduced their survival by directly targeting F11R/JAM-A. The result was a notable hindrance in the metastasis process in the mouse models used for the study.

This breakthrough has significant implications. The success of P4D in these preliminary studies suggests potential for future clinical trials and paves the way for more targeted, effective treatments for TNBC, possibly extending to the development of tailored antibodies. LifeTein’s contribution to this field exemplifies its commitment to advancing cancer therapy, offering new hope to those battling with TNBC.

For more detailed insights, refer to the original study by Bednarek, R., Wojkowska, D.W., Braun, M. et al., titled “Triple negative breast cancer metastasis is hindered by a peptide antagonist of F11R/JAM‑A protein,” published in Cancer Cell International.

Bednarek, R., Wojkowska, D.W., Braun, M. et al. Triple negative breast cancer metastasis is hindered by a peptide antagonist of F11R/JAM‑A protein. Cancer Cell Int 23, 160 (2023).

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Research context

Read sources and limitations before applying a claim.

Structural Studies

Rigid spacers help stabilize peptide conformations in NMR or crystallography studies, providing more precise structural data.Find out more about peptide synthesis here.

Source: lifetein.com ↗

Case Studies and Examples

One notable example is the development of a peptide-based vaccine for the H1N1 influenza virus. Researchers have identified a killer decapeptide (KP) with potent action against the virus. When combined with PADRE, this vaccine has shown improved efficacy in reducing viral levels and improving survival rates in animal models. Applications in Autoimmune Diseases Modulating Immune Responses The PADRE peptide has shown potential in the treatment of autoimmune diseases by modulating immune responses. In conditions such as rheumatoid arthritis and multiple sclerosis, the immune system mistakenly attacks the body’s own tissues. By incorporating PADRE into therapeutic strategies, researchers aim to redirect the immune response, reducing inflammation and tissue damage. Preclinical and Clinical Studies Preclinical studies have demonstrated that PADRE can induce regulatory T-cells (Tregs), which play a crucial role in maintaining immune tolerance. These findings have paved the way for clinical trials exploring PADRE-based therapies for autoimmune diseases. Early results indicate that PADRE can help restore immune balance, offering a promising avenue for treatment. Applications in Allergy Treatments Reducing Allergic Reactions In allergy treatments, the PADRE peptide is used to reduce hypersensitivity reactions. By enhancing the immune system’s ability to tolerate allergens, PADRE can help mitigate symptoms associated with allergic conditions such as asthma and food allergies. Immunotherapy Approaches Immunotherapy approaches incorporating PADRE have shown efficacy in desensitizing patients to specific allergens. For example, PADRE-based vaccines targeting peanut allergies have demonstrated the ability to reduce allergic reactions in clinical trials. These vaccines work by gradually exposing the immune system to the allergen in a controlled manner, promoting tolerance.Find the PADRE Peptide here. Future Directions and Research Expanding Therapeutic Applications Ongoing research aims to expand the therapeutic applications of the PADRE peptide. Scientists are exploring its potential in areas such as transplantation medicine, where PADRE could help prevent organ rejection by modulating the immune response. Additionally, PADRE is being investigated for its role in enhancing the efficacy of DNA vaccines and mRNA vaccines, which have gained prominence in recent years. Innovative Delivery Systems Innovative delivery systems are being developed to improve the stability and efficacy of PADRE-based therapies. These include nanoparticle-based delivery and liposomal formulations, which can enhance the bioavailability and targeted delivery of PADRE to specific tissues. Frequently Asked Questions What is the primary function of the PADRE peptide? The primary function of the PADRE peptide is to bind to MHC class II molecules, enhancing the activation of helper T-cells and boosting immune responses. How is PADRE used in cancer immunotherapy? In cancer immunotherapy, PADRE is incorporated into peptide-based vaccines to improve the presentation of tumor antigens to the immune system, leading to a more effective anti-tumor response. Can PADRE be used in the treatment of autoimmune diseases? Yes, PADRE has shown potential in modulating immune responses in autoimmune diseases, helping to reduce inflammation and tissue damage. What are some examples of PADRE’s applications in allergy treatments? PADRE is used in immunotherapy approaches to reduce allergic reactions, such as in vaccines targeting peanut allergies, which promote immune tolerance to the allergen. What future research directions are being explored for PADRE? Future research is exploring PADRE’s potential in transplantation medicine, DNA and mRNA vaccines, and innovative delivery systems like nanoparticle-based and liposomal formulations.

Source: lifetein.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

How-to reference

How to solubilize my synthetic peptides? #

Please refer to this FAQ for details: Handling and Storage of Synthetic Peptides. If the peptides are still cloudy, or turbid, you may have reached the limit of solubility. When the peptides are insoluble in the buffer, please try to sonicate, centrifuge, and lyophilize the peptide. Make sure to break the lyophilized lumps into a fine powder. Then try a small volume of a good agent 8M Urea, NMP, DMF, or DMSO to dissolve the peptide. Then dilute with water or your desired buffer. For peptides with Arg or LYs, you should try to lower the pH to 6 because the protonated amino acids will help solubility. Sonication and the following solvents may help with difficult peptides: 1) Begin with 100 % acetonitrile then dilute with water until 50% 2) Begin with 100% DMSO then dilute with water until 30 % 3) Dissolve it with 8M Urea 4) Dissolve it with 6 or 8 M Guanidine hydrochloride 5) 6M GuHCL, 0.05% TFA, pH2, 6) 100% TFA 7) 40% AcOH, 30%ACN, 30% water

Source: lifetein.com ↗
Storage reference

Enhanced Stability

Cyclic peptides are known for their conformational rigidity, which makes them less susceptible to enzymatic degradation. This increased stability is particularly beneficial for therapeutic applications where peptides need to remain intact longer in the body.

Source: lifetein.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →